PDCD1 and esophageal cancer: Monotherapy with immune checkpoint inhibitors (ICIs) including anti-programmed cell death-1 (PD-1) antibodies, nivolumab and pembrolizumab, has recently been introduced as a standard second-line treatment for advanced esophageal cancer [3, 4].